Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
134.79
+0.04 (0.03%)
Aug 21, 2026, 9:14 AM EDT - Market open
Apogee Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 105.57 | 131.55 | 141.79 | 118.32 | 151.89 |
Short-Term Investments | 866.36 | 598.64 | 378.86 | 277.14 | - |
Cash & Short-Term Investments | 971.93 | 730.19 | 520.65 | 395.46 | 151.89 |
Cash Growth | 92.30% | 40.24% | 31.66% | 160.36% | - |
Other Receivables | 9.59 | 5.96 | 4.7 | 1.21 | - |
Receivables | 9.59 | 5.96 | 4.7 | 1.21 | - |
Prepaid Expenses | 8.78 | 4.6 | 2.62 | 1.74 | 0.11 |
Other Current Assets | 1.44 | 0.61 | 1.74 | - | 0.06 |
Total Current Assets | 991.73 | 741.36 | 529.71 | 398.41 | 152.06 |
Property, Plant & Equipment | 11.53 | 14.38 | 13.32 | 2.59 | - |
Long-Term Investments | 321.94 | 172.73 | 210.42 | - | - |
Other Long-Term Assets | 10.61 | 8.67 | 0.5 | 0.4 | - |
Total Assets | 1,336 | 937.13 | 753.95 | 401.4 | 152.06 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 3.08 | 1.22 | 1.07 | 2.14 | 0.42 |
Accrued Expenses | 32.07 | 23.18 | 24.26 | 17.31 | 9.56 |
Current Portion of Leases | 2.37 | 3.5 | 3.23 | 1.1 | - |
Total Current Liabilities | 37.51 | 27.91 | 28.56 | 20.56 | 9.98 |
Long-Term Leases | 4.47 | 5.35 | 8.6 | 0.93 | - |
Total Liabilities | 141.21 | 33.25 | 37.16 | 21.49 | 9.98 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0 | 0 | 0 | - | 2.25 |
Additional Paid-In Capital | 1,919 | 1,465 | 1,022 | 503.35 | - |
Retained Earnings | -721.72 | -561.76 | -305.92 | -123.77 | -39.79 |
Comprehensive Income & Other | -2.5 | 1.08 | 0.92 | 0.33 | 2.14 |
Total Common Equity | 1,195 | 903.88 | 716.79 | 379.91 | -35.39 |
Shareholders' Equity | 1,195 | 903.88 | 716.79 | 379.91 | 142.08 |
Total Liabilities & Equity | 1,336 | 937.13 | 753.95 | 401.4 | 152.06 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 6.83 | 8.85 | 11.83 | 2.03 | - |
Net Cash (Debt) | 1,287 | 894.07 | 719.24 | 393.43 | 151.89 |
Net Cash Growth | 110.87% | 24.31% | 82.82% | 159.02% | - |
Net Cash Per Share | 18.98 | 14.73 | 13.03 | 15.73 | 61.69 |
Filing Date Shares Outstanding | 75.42 | 68.85 | 58.09 | 48.52 | 5 |
Total Common Shares Outstanding | 75.07 | 68.4 | 58.06 | 48.52 | 5 |
Working Capital | 954.22 | 713.45 | 501.15 | 377.85 | 142.08 |
Book Value Per Share | 15.91 | 13.21 | 12.35 | 7.83 | -7.08 |
Tangible Book Value | 1,195 | 903.88 | 716.79 | 379.91 | -35.39 |
Tangible Book Value Per Share | 15.91 | 13.21 | 12.35 | 7.83 | -7.08 |
Machinery | 4.13 | 4.22 | 1.29 | - | - |
Leasehold Improvements | 3.08 | 3.08 | 0.86 | - | - |